Acetyl-TP53 (K381) Antibody

What is the Acetyl-TP53 (K381) Antibody and what does it detect?

The Acetyl-TP53 (K381) antibody specifically recognizes the tumor suppressor protein p53 when it is acetylated at lysine 381 (K381) in its C-terminal domain. This antibody is generated using synthetic peptides corresponding to regions surrounding K381 of human p53 . The specificity of these antibodies is critical - they detect endogenous levels of p53 protein only when acetylated at K381 and not when in unmodified form . This post-translational modification plays a significant role in p53's ability to regulate cell cycle arrest, DNA repair, and apoptosis functions .

What applications are commonly used with Acetyl-TP53 (K381) Antibody?

The Acetyl-TP53 (K381) antibody has been validated for multiple research applications:

For Western blot applications, researchers should note that while the calculated molecular weight of p53 is approximately 44 kDa, the observed band typically appears at 53 kDa . This size discrepancy occurs because mobility in gel electrophoresis can be affected by post-translational modifications and protein conformation .

How does acetylation at K381 affect p53 function?

Acetylation at K381 plays several crucial roles in p53 regulation:

• It increases during DNA damage response and correlates with p53 activation and stabilization

• It can influence p53 protein conformation, affecting binding to co-factors like 53BP1 and p300

• It works alongside other modifications to determine p53's cellular fate decisions (apoptosis vs. cell cycle arrest)

• In mutant p53 forms, acetylation at K381 (along with K373 and K382) can rescue tumor suppression functions, particularly in non-small cell lung cancers

Research using constitutively acetylated mimetics (K-to-Q mutations) versus non-acetylatable mutants (K-to-R mutations) demonstrates that the acetylation status of the C-terminal domain, including K381, significantly impacts p53 protein stability .

How does K381 acetylation influence p53 protein conformation?

Structural studies have revealed fascinating insights about how K381 acetylation affects p53 conformation:

• Acetylation at K381, especially when combined with K382 dimethylation, induces an α-helical structure in the p53 C-terminal domain

• This structural change positions the side chains of R379, K381ac, and K382me2 to interact concurrently with binding partners like the tandem Tudor domain (TTD) of 53BP1

• Crystal structure analysis at 1.8 Å resolution shows the p53K381acK382me2 peptide folding into an α-helix positioned near the top of the first β-barrel of the TTD

• This conformation is stabilized through characteristic hydrogen bonds involving R379, K381ac, K382me2, L383, and F385 residues

This conformational change mechanism operates as a molecular switch that regulates which binding partners p53 interacts with under different cellular conditions, potentially affecting downstream signaling pathways .

What is the interplay between K381 acetylation and other nearby modifications?

The p53 C-terminal domain undergoes multiple post-translational modifications that function in concert:

• K381 acetylation enhances recognition of K382 dimethylation by specific antibodies, suggesting these modifications influence each other structurally

• The K381ac-K382me2 dual modification creates a unique binding interface for protein interactions distinct from either modification alone

• Binding affinity measurements show that K381ac has only a small effect on binding free energy to the TTD of 53BP1 compared to K382me2 alone (Kd = 760 nM vs. 900 nM)

• Phosphorylation of nearby serine/threonine residues (T377, S378) can also affect these interactions

• Unlike K381ac, phosphorylation at T377 or S378 does not enhance recognition of K382me2

Research with constitutively acetylated mimetics demonstrates that these modifications work together to regulate p53 stability and function in response to cellular stress .

How can researchers validate Acetyl-TP53 (K381) Antibody specificity?

Proper validation is essential for accurate interpretation of results:

• Dot blot analysis:

  • Synthesize peptides with different modification patterns (unmodified, K381ac only, K382me2 only, and K381acK382me2)

  • Spot dilutions onto nitrocellulose membrane

  • Probe with anti-p53K381ac antibody

  • Compare reactivity patterns

• Peptide microarray analysis:

  • Print biotinylated p53 CTD peptides (residues 366-390) with various modifications on streptavidin-coated slides

  • Probe with Acetyl-TP53 (K381) antibody

  • Analyze reactivity patterns to confirm specificity

• Cell-based validation:

  • Compare reactivity in cells treated with and without deacetylase inhibitors like Trichostatin A (TSA)

  • Include DNA damage agents like doxorubicin to induce p53 modifications

  • Use p53-null cell lines as negative controls

• Genetic models:

  • Utilize cell lines expressing wild-type p53 versus acetylation-mimicking mutants (K-to-Q) or non-acetylatable mutants (K-to-R)

What are the critical experimental controls when working with Acetyl-TP53 (K381) Antibody?

Robust experimental design requires appropriate controls:

Additionally, researchers should include standard Western blot loading controls and optimize antibody concentration for each specific application .

How does DNA damage influence p53 K381 acetylation?

DNA damage response triggers complex p53 modification patterns:

• Doxorubicin (a DNA damage agent) treatment substantially increases p53 acetylation, including at K381

• Combined treatment with doxorubicin and deacetylase inhibitors like TSA further enhances acetylation levels

• Unlike K382me2, which increases dramatically after ionizing radiation, K381ac levels may remain relatively stable in some experimental systems

• The presence of K381ac can influence the recognition of other modifications like K382me2, potentially creating a sequential modification pattern following DNA damage

This dynamic interplay between acetylation and other modifications following DNA damage helps orchestrate appropriate cellular responses, determining whether cells undergo repair, cell cycle arrest, or apoptosis .

Western Blotting Protocol:

• Prepare whole cell lysates from experimental samples

• Separate proteins using SDS-PAGE (expect p53 band at approximately 53 kDa)

• Transfer to nitrocellulose membrane

• Block with 1% BSA in PBS-T for 1 hour

• Incubate with Acetyl-TP53 (K381) antibody at 1:500-1:2000 dilution

• Wash 5 times with PBS-T

• Incubate with HRP-conjugated secondary antibody

• Develop with ECL substrate

Immunohistochemistry Protocol:

• Prepare formalin-fixed paraffin-embedded tissue sections

• Perform heat-mediated antigen retrieval with sodium citrate buffer (pH 6.0)

• Block endogenous peroxidase activity

• Incubate with Acetyl-TP53 (K381) antibody at 1:100-1:300 dilution

• Detect using an HRP-conjugated compact polymer system

• Develop with DAB chromogen

• Counterstain with hematoxylin and mount with DPX

Immunofluorescence Protocol:

• Fix cells with formalin

• Permeabilize with 0.1% Triton X-100 in TBS for 5-10 minutes

• Block with 3% BSA-PBS for 30 minutes

• Incubate with Acetyl-TP53 (K381) antibody (1:200-1:1000) in 3% BSA-PBS overnight at 4°C

• Wash with PBST

• Incubate with fluorophore-conjugated secondary antibody

• Mount and visualize by fluorescence microscopy

How should researchers troubleshoot inconsistent results with Acetyl-TP53 (K381) Antibody?

When encountering inconsistent results, consider:

• Antibody-related issues:

  • Check antibody storage conditions (avoid freeze-thaw cycles)

  • Verify batch consistency with standard positive controls

  • Optimize concentration for your specific application and cell type

• Sample preparation factors:

  • Include deacetylase inhibitors during lysis to preserve acetylation

  • Ensure complete protein extraction, especially for nuclear proteins

  • Consider the timing of sample collection after treatments (acetylation is dynamic)

• Technical considerations:

  • For Western blots: Check transfer efficiency and blocking conditions

  • For IHC/IF: Optimize antigen retrieval and fixation methods

  • Ensure secondary antibody compatibility and specificity

• Biological variables:

  • Consider cell type-specific differences in p53 regulation

  • Account for variations in treatment response timing

  • Remember that acetylation patterns differ between cellular stress conditions

How is Acetyl-TP53 (K381) Antibody used in cancer research?

The antibody has significant applications in oncology research:

• Detecting acetylation changes in mutant p53 forms found in non-small cell lung cancers

• Monitoring p53 activation status in response to DNA-damaging chemotherapeutic agents

• Examining the relationship between histone deacetylase inhibitors and p53 acetylation patterns

• Investigating how acetylation rescues tumor suppression functions in p53 mutants

• Studying how acetylation affects p53 aggregation in cancer cells

Researchers have demonstrated that constitutive acetylation mimetics of p53 (3KQ mutants) show altered stability and function compared to non-acetylatable forms (6KR mutants) in cancer cell models .

What recent advances have emerged in understanding p53 K381 acetylation?

Recent research has revealed:

• An acetyl-methyl switch mechanism where K381 acetylation works with K382 dimethylation to drive conformational changes in p53

• The role of K381 acetylation in preventing mutant p53 aggregation in cancer cells

• Structural insights into how the α-helical conformation induced by K381 acetylation creates specific protein interaction interfaces

• The differential stability of p53 with constitutively acetylated CTD (3KQ) versus non-acetylatable CTD (6KR) in cycloheximide chase experiments

These findings continue to expand our understanding of how post-translational modifications fine-tune p53 function in both normal and disease states.